XPRIZE Healthspan: Jamie Justice on functional aging metrics and a $101 million race
In this video description, XPRIZE Healthspan Executive Director Jamie Justice tells Brianna Stubbs about a $101 million competition aiming to restore 10 years of muscle, cognitive and immune function within one year, and about moving beyond binary alive-or-dead measures toward functional independence. [1]
Automatic summary · not editorially reviewed
The key findings
The description presents a $101 million XPRIZE Healthspan race to restore 10 years of muscle, cognitive and immune function within a single year. [1]
The conversation is said to move past binary alive-or-dead metrics, called the "toes test" in animal research, toward functional independence through clinical trial innovation. [1]
The description says the discussion covers accessible markers such as RDW, risks of overlapping treatments and unlocking "dark data". [1]
The source at a glance
- Study type / format
- Video description of a discussion interview
- Population / context
- Viewers of a conversation between Jamie Justice and Brianna Stubbs about XPRIZE Healthspan; no study participants are described.
- Summary based on
- Creator description
- Original publication
- February 18, 2026
Justice and Stubbs on the $101 million healthspan race
The description presents Jamie Justice, Executive Director of XPRIZE Healthspan, in conversation with Brianna Stubbs. The stated aim is a $101 million race to restore 10 years of muscle, cognitive and immune function within a single year. Justice is also described as Executive Vice President of the Health Domain at XPRIZE Foundation and as an adjunct professor in gerontology and geriatric medicine at Wake Forest University School of Medicine, where she works on geroscience — the hypothesis that targeting the basic biology of aging could delay or prevent multiple age-related diseases.
Supporting source [1]
Beyond the toes test: RDW, overlapping treatments, dark data
According to the description, the conversation moves past binary alive-or-dead metrics, called the "toes test" in animal research, and focuses on reclaiming functional independence through clinical trial innovation. It explores the potential of accessible markers such as RDW (Red Cell Distribution Width), the risks of overlapping treatments, and how unlocking "dark data" could help shift medicine from treating isolated diseases to scaling human healthspan globally. These are topics the description says are discussed; it reports no results, effect sizes or trial outcomes.
Supporting source [1]
Description-only scope of the Justice and Stubbs conversation
This explainer relies solely on the supplied video description. The video and transcript were not reviewed, so the framing of the competition, the discussion of RDW, overlapping treatments and dark data, and any statements about restoring function are attributed to the description and its speakers, not verified here. The description gives no study design, sample, follow-up or measured outcomes, and it does not establish that any intervention restores function or extends healthspan in people.
Supporting source [1]
How to interpret this
Only the video description was supplied; the video and transcript were not reviewed. The description reports topics discussed, not study design, sample, follow-up or measured outcomes, and it does not establish that any intervention restores function or extends human healthspan.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Buck Institute for Research on Aging · youtube.com · February 18, 2026